CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

CVM 1.96 +0.06 (3.16%)
price chart
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
CEL-SCI Corporation Releases Letter to Shareholders
Our Phase 3 study in advanced primary (untreated) head and neck cancer patients with the investigational drug Multikine* (Leukocyte Interleukin Inj.
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer study ...
CEL-SCI Announces Adjustment to Warrant Exercise Price
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 ...
Cel Sci Corporation (NYSEAMERICAN:CVM)'s Stock Is Buy After Less Market ...  Frisco Fastball
CEL-SCI Co. (CVM) Short Interest Update  The Lincolnian Online
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate ...
CEL-SCI's LEAPS vaccine for the treatment of rheumatoid arthritis received a $1.5 million grant from the U.S. National Institutes of Health (NIH).
$0.52 EPS Expected for BofI Holding, Inc. (BOFI); Cel Sci (NYSEAMERICAN:CVM ...  Wolcott Daily
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
Traders Take Note: Cel-Sci Corporation (AMEX:CVM) Stock Drops, Weakness in ...
Take Note: Cel-Sci Corporation (AMEX:CVM) has hit some technical weakness in its momentum, and while it has not broken down all the way through support -- watch the key levels that we discuss below and further, watch the stochastics and technical ...
Analysts Layout Best- And Worst-Case Scenarios: CEL-SCI Corporation (CVM ...  Post Analyst
Analyst Stock Recommendations For Akoustis Technologies, Inc. (AKTS), CEL ...  Analyst Journal
CEL-SCI Reports Recent Data Review By the Independent Data Monitoring ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine ...
CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head ...  Seeking Alpha
CEL-SCI Announces Update on Arbitration against Former Clinical Research ...
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...